Co-Authors
This is a "connection" page, showing publications co-authored by CHARLES LU and MARGARET SPITZ.
Connection Strength
0.537
-
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65.
Score: 0.082
-
Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006 Jan 15; 106(2):441-7.
Score: 0.067
-
Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk. Am J Epidemiol. 2005 Mar 01; 161(5):412-22.
Score: 0.063
-
Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharmacogenomics J. 2014 Dec; 14(6):509-22.
Score: 0.030
-
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.
Score: 0.030
-
Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. Carcinogenesis. 2011 Dec; 32(12):1867-71.
Score: 0.025
-
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis. 2011 Jul; 32(7):1050-6.
Score: 0.024
-
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25.
Score: 0.024
-
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
Score: 0.023
-
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011 Jan; 71(1):82-8.
Score: 0.023
-
Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer. 2008 May 20; 98(10):1716-22.
Score: 0.020
-
ATM sequence variants associate with susceptibility to non-small cell lung cancer. Int J Cancer. 2007 Nov 15; 121(10):2254-9.
Score: 0.019
-
Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res. 2007 Oct 01; 13(19):5974-81.
Score: 0.019
-
Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1517-22.
Score: 0.019
-
Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15; 12(24):7329-38.
Score: 0.018
-
Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5720-5.
Score: 0.018
-
Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 2007 Feb; 28(2):350-5.
Score: 0.018
-
High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
Score: 0.016